SCHEMBL2803952

SCHEMBL2803952

O=C(Nc1cccc(F)c1)N1CCc2c(cnc3[nH]ncc23)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.56
CYP2D6 P10635 3/20 0.47
USP2 O75604 3/20 0.47
ALOX15 P16050 1/20 0.47
PAK1 Q13153 1/20 0.47
FAAH O00519 2/20 0.46
GPR142 Q7Z601 1/20 0.45
HTT P42858 2/20 0.45
MAPK1 P28482 1/20 0.45
MKNK1 Q9BUB5 1/20 0.45
FLT3 P36888 1/20 0.45
CYP3A4 P08684 3/20 0.45
CYP2C19 P33261 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 3/20 0.45
LMNA P02545 2/20 0.44
MAPT P10636 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2805021 0.90 PAK1 (0.43) TRPV1PAK1SMN1; SMN2NPC1RAB9A
SCHEMBL2806010 0.88 TRPV1 (0.56) TRPV1PAK1FAAHLMNAMAPT
SCHEMBL2805561 0.88 KDR (0.51) TRPV1PAK1FAAHSMN1; SMN2ALDH1A1
SCHEMBL2805002 0.88 PAK1 (0.60) USP2PAK1FAAHGPR142SMN1; SMN2
SCHEMBL2486602 0.88 RAB9A (0.55) TRPV1PAK1MAPK1SMN1; SMN2ALDH1A1
SCHEMBL2802923 0.88 TRPV1 (0.58) TRPV1PAK1FAAHGPR142HTT
SCHEMBL2806850 0.87 RAB9A (0.60) TRPV1PAK1MAPK1SMN1; SMN2LMNA
SCHEMBL2487737 0.87 NPC1 (0.49) TRPV1PAK1FAAHSMN1; SMN2NPC1
SCHEMBL2805093 0.87 PAK1 (0.44) TRPV1PAK1NPC1RAB9A
SCHEMBL2488604 0.86 BRAF (0.52) TRPV1PAK1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 TRPV1 1732/4885CYP2D6 251/4885USP2 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.